Stock Deep Dive · 2026-08-07
Samsung Biologics (207940) closed at ₩1,556,000, up 2.77% on the day. Year-to-date return is -8.2%, sitting at 43% of its 52-week range. Next earnings: 2026-10-27 (in 81 days). Listed in Seoul — for USD-based investors, KRW moves add an FX layer on top of the stock’s local return.
|
Close
₩1,556,000
+2.77% · YTD -8.2%
|
Market Cap
₩72.03T
Biotechnology
|
Forward P/E
31.6x
PER 38.4x
|
52-wk Range
43%
High ₩1,987,000 · Low ₩1,228,000
|
🔍 At a Glance
Samsung Biologics pairs 30.2% YoY revenue growth with a striking 47.9% operating margin and 18.2% ROE, and its 25-analyst consensus (strong buy, average target ₩1,975,520) implies meaningful upside from the current ₩1,556,000. Yet the stock is still down 8.2% YTD and trades on demanding multiples (PER 38.4, PSR 16.0, PBR 9.7), with RSI at 67.4 signaling the recent 1-month +14.2% rally may be getting stretched, and shares remain 3.3% below their 200-day average.
🏢 How It Makes Money
As a KOSPI-listed CDMO (contract development and manufacturing organization) under the Samsung group umbrella, the company earns fees for developing and manufacturing biologics — cell line development, process/analytical development, GMP manufacturing, fill-finish, and quality testing — for global pharma clients, with newer bets on antibody-drug conjugates and mRNA. It is a manufacturing-capacity business, not a drug-royalty one, distinct from Samsung’s other biotech-adjacent entities (as one headline clarifies versus “Samsung Epics Holdings”).
📈 Quarterly Results — Is Business Growing?
| Quarter | Revenue | Op. Income | Net Income | Op. Margin |
|---|---|---|---|---|
| 25Q1 | ₩999.5B | ₩430.2B | ₩375.6B | 43.0% |
| 25Q2 | ₩1.29T | ₩475.6B | ₩324.4B | 36.9% |
| 25Q3 | ₩1.66T | ₩728.8B | ₩574.5B | 43.9% |
| 25Q4 | ₩308.6B | ₩378.1B | ₩510.0B | 122.5% |
| 26Q1 | ₩1.26T | ₩580.8B | ₩469.2B | 46.2% |
| 26Q2* | ₩1.32T | ₩586.4B | ₩430.7B | 44.4% |
* 26Q2 figures come from the company’s preliminary earnings disclosure filed with Korea’s DART on 2026-07-23. They are unaudited and will be replaced once the reviewed quarterly or half-year report is filed.
Latest-quarter revenue up +30.2% versus the same quarter a year ago.
💡 Korea Market 101
⚖️ Valuation — Cheap or Expensive?
| Metric | Value | How to read it |
|---|---|---|
| P/E (trailing) | 38.4x | Price vs last 12 months’ earnings |
| P/E (forward) | 31.6x | Price vs next 12 months’ expected earnings — growth hopes baked in |
| P/S | 16.0x | Price vs revenue — for high-growth names with thin profits |
| P/B | 9.7x | Price vs book value — below 1x means priced under liquidation value |
| PEG | 2.3x | P/E ÷ growth — near 1 is fair for the growth; above 2 is demanding |
| EV/EBITDA | 25.0x | Enterprise value (incl. debt) vs cash generation |
Peer comparison
| Name | Mkt Cap | P/E | Fwd P/E | P/S |
|---|---|---|---|---|
| SAMSUNG BIOLOGICS | ₩72.03T | — | 31.6x | 15.0x |
| Celltrion | ₩45.70T | — | 26.4x | 10.2x |
💡 Korea Market 101
🎯 Street Consensus
- Price target (mean): ₩1,975,520
- Target high / low: ₩2,200,000 / ₩1,600,000
- Implied upside: +27.0%
- Rating: Strong Buy (1.4/5)
- Analysts covering: 25
- Next earnings: 2026-10-27
💡 Korea Market 101
📉 Price Action — Technical Check
| Indicator | Value | How to read it |
|---|---|---|
| RSI (14d) | 67.4 | Above 70 overbought · below 30 oversold |
| vs 60-day MA | +11.6% | Above/below the medium-term trend |
| vs 200-day MA | -3.3% | Above/below the long-term trend |
| Golden/death cross | 50-day below 200-day (bearish alignment) | 50-day MA crossing above (golden) or below (death) the 200-day |
| Volume (vs 20d avg) | 0.8x | 2x+ means a spike in market attention |
💡 Korea Market 101
📰 Recent News
- Why is Samsung Biologics stock sliding today? — Investing.com
- [Confusing Can Cost You] Samsung Biologics vs Samsung Epics Holdings: The Split Rule Between “Factory Utilization” and “New Drug Patents” — theconnectmoney.com
- Samsung Biologics Acquires PolyPeptide Group for $1.8 Billion — Briefs Finance
- Samsung Biologics agrees $1.81bn takeover of PolyPeptide — pharmaphorum
- Samsung Biologics To Acquire PolyPeptide For CHF 1.46 Billion — Pulse 2.0
- Samsung Biologics Should See Steady Growth Backed by Visible Project Pipeline and Increased Capacity — Morningstar
How to read these headlines
The common thread is strategic expansion meeting investor scrutiny: the PolyPeptide deal broadens Samsung Biologics into peptide manufacturing, which Morningstar frames as supporting a “visible project pipeline,” but the near-term share slide and structural confusion versus Samsung Epics Holdings suggest the market is still digesting financing terms and corporate-structure clarity — both of which can weigh on sentiment even as underlying fundamentals stay strong.
Headlines are credited to their publishers — click a headline to open the original article. The commentary is written by this site and does not represent the views of any publisher.
💡 Korea Market 101
🔭 Scenarios & What to Watch
Watch the next earnings release on 2026-10-27 for confirmation that the 30%+ revenue growth pace and 47.9% margin hold as new capacity ramps. The pending $1.8bn (CHF 1.46bn) PolyPeptide acquisition adds peptide-manufacturing scale but brings integration and financing costs, plus CHF/KRW FX exposure worth tracking for USD-based investors already managing KRW translation risk. A pullback toward the 200-day average or analyst low-end target (₩1,600,000) versus a push toward the ₩2,200,000 high-end would clarify whether momentum or valuation concerns dominate.
Next earnings on 2026-10-27 (in 81 days) — guidance usually decides the stock’s direction more than the reported quarter.
💡 Korea Market 101
📚 All stock analysis · More on Samsung Biologics · Market report for this session
Stock report · published 2026-08-07 16:00 KST
For information only — a summary of public data, not a recommendation to buy or sell any security. Source data (Yahoo Finance and others) may be delayed or contain errors. All investment decisions are your own responsibility.
Leave a Reply